LCAR-AMDR / Legend Biotech - LARVOL DELTA

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | N=34 ➔ 4 | Trial completion date: Feb 2027 ➔ Sep 2023 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2025 ➔ Sep 2023; Both the sponsors and collaborator are considering terminating the study

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=34 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New P1 trial • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology